These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Bruton's tyrosine kinase is a possible therapeutic target in microscopic polyangiitis. Nakade I; Tamura Y; Hashimoto F; Ariza Y; Hotta S; Fujigaya H; Arai S; Taniguchi M; Ogawa H; Nishibata Y; Masuda S; Nakazawa D; Tomaru U; Ishizu A Arthritis Res Ther; 2023 Nov; 25(1):215. PubMed ID: 37932784 [TBL] [Abstract][Full Text] [Related]
7. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy. Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376 [TBL] [Abstract][Full Text] [Related]
9. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors. Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181 [TBL] [Abstract][Full Text] [Related]
10. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma. He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096 [TBL] [Abstract][Full Text] [Related]
11. Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies. Goodstal SM; Lin J; Crandall T; Crowley L; Bender AT; Pereira A; Soloviev M; Wesolowski JS; Iadevaia R; Schelhorn SE; Ross E; Morandi F; Ma J; Clark A Sci Rep; 2023 Nov; 13(1):20412. PubMed ID: 37989777 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575 [TBL] [Abstract][Full Text] [Related]
13. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458 [TBL] [Abstract][Full Text] [Related]
14. Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib. Lin DY; Andreotti AH PLoS One; 2023; 18(8):e0290872. PubMed ID: 37651403 [TBL] [Abstract][Full Text] [Related]
15. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML. Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. Han YB; Yang JM; Kwon HJ; Lee JO; Lee JS; Paik JH Anticancer Res; 2021 Nov; 41(11):5677-5692. PubMed ID: 34732441 [TBL] [Abstract][Full Text] [Related]
18. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766 [TBL] [Abstract][Full Text] [Related]
19. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378 [TBL] [Abstract][Full Text] [Related]
20. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells. Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]